Balance Sheet StrengthA robust equity position and low debt-to-equity provide durable financial resilience. This reduces refinancing risk, preserves borrowing capacity for working capital or targeted investments, and gives management flexibility to withstand sector volatility over the next several quarters.

Diversified Revenue Streams & BrandThe firm sells OTC consumer products (notably digestive health), prescription drugs and other healthcare items, creating diversified channels across retail and medical distribution. This multi-channel model stabilizes revenue sources and lowers reliance on any single channel over a medium-term horizon.

Recent Revenue Uptick And EBITDA ImprovementA recent ~16.8% revenue increase alongside reported EBITDA margin improvement suggests operational stabilization. If sustained, these trends can restore intermediate profitability and support cash generation, enabling reinvestment in marketing or product development over coming quarters.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow shows earnings are not converting to cash efficiently. Over 2-6 months this constrains working capital, limits ability to fund capex or pay dividends, and raises dependence on external financing, increasing liquidity and refinancing risk.

Declining Profitability And Negative EBITFalling net income and a negative EBIT margin point to structural operating weakness or unfavorable mix. Continued margin pressure diminishes retained earnings for reinvestment, undermines return metrics, and requires structural fixes to restore sustainable profitability.

Long-term Revenue Decline And Weakening ROEAlthough short-term revenue rose, the company shows a longer-term revenue decline and diminishing ROE. Sustained top-line contraction reduces scale benefits, limits margin recovery, and constrains the firm’s ability to fund growth initiatives, perpetuating a low-growth profit profile.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥270.00 and its highest was ¥371.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥11.56B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 18, 2026 which is in 72 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Feb 04, 2026. The company reported ¥10.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥10.05.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3 which represents an annual dividend yield of 1.06%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥10.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.